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ABSTRACT
Genome-wide association studies (GWAS), relying
on hundreds of thousands of individuals, have re-
vealed >200 genomic loci linked to metabolic dis-
ease (MD). Loss of insulin sensitivity (IS) is a key
component of MD and we hypothesized that discov-
ery of a robust IS transcriptome would help reveal
the underlying genomic structure of MD. Using 1,012
human skeletal muscle samples, detailed physiology
and a tissue-optimized approach for the quantifica-
tion of coding (>18,000) and non-coding (>15,000)
RNA (ncRNA), we identified 332 fasting IS-related
genes (CORE-IS). Over 200 had a proven role in the
biochemistry of insulin and/or metabolism or were
located at GWAS MD loci. Over 50% of the CORE-IS
genes responded to clinical treatment; 16 quantita-
tively tracking changes in IS across four indepen-
dent studies (P = 0.0000053: negatively: AGL, G0S2,
KPNA2, PGM2, RND3 and TSPAN9 and positively:
ALDH6A1, DHTKD1, ECHDC3, MCCC1, OARD1,
PCYT2, PRRX1, SGCG, SLC43A1 and SMIM8). A net-
work of ncRNA positively related to IS and interacted
with RNA coding for viral response proteins (P < 1 ×
10−48), while reduced amino acid catabolic gene ex-
pression occurred without a change in expression of
oxidative-phosphorylation genes. We illustrate that
combining in-depth physiological phenotyping with
robust RNA profiling methods, identifies molecular
networks which are highly consistent with the genet-
ics and biochemistry of human metabolic disease.
INTRODUCTION
Nucleic acid profiling technologies combined with systems
biology and in-depth clinical phenotyping provide unpar-
alleled opportunities to study mechanisms of human dis-
ease (1–6). Type 2 diabetes (T2DM), whose increased preva-
lence is proposed to be driven by obesity (7), is a complex
metabolic disease involving gene-environment interactions
reflective of excess nutrient intake, insufficient physical ac-
tivity and, potentially, ageing. A feature of T2DM is a vari-
able loss of peripheral insulin sensitivity (IS) (8,9); in hu-
mans predominantly reflecting reduced efficacy of insulin
signaling (‘insulin resistance’, IR) in skeletal muscle and
liver (10,11). GWAS analyses have revealed >200 genomic
loci linked to phenotypes underpinning the pathophysiol-
ogy of T2DM (12). In turn, these loci provide a link to
thousands of potential ‘disease’ genes as, by design, GWAS
projects do not identify the individual gene responsible for
the genetic association (13–15). One recent T2DM GWAS
analysis identified 128 markers across 113 genomic loci us-
ing 26,676 T2DM cases and 132,532 controls, with an ad-
ditional ∼70,000 samples used for post-hoc validation (16).
Follow-up informatics analysis suggested these loci harbor
genes that predominantly impact on insulin secretion and
adipocyte or hepatocyte biology.However, estimation of the
causal risk genes is currently imprecise (13,14), constrain-
ing the contextualization of GWAS results, such that addi-
tional lines of evidence to help identify the most likely ‘dis-
ease gene’ at otherwise validated loci, is warranted (15,17).
Recent efforts to apply expression quantitative trait loci
(eQTL) analysis to the genomics of metabolic disease has
yielded limited progress (18), and this probably reflects the
reported assumptions limiting the sensitivity of eQTL anal-
ysis (19), as well as suboptimal tissue transcriptomics.
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Direct quantification of the human coding and non-
coding transcriptome in tissues physiologically responsible
for regulating IS provides an alternative, and more quan-
titative route to associate individual genes with the ge-
nomics underpinning metabolic disease (20). Furthermore,
characterizing the transcriptional response to treatments
which improve IS, would support a causal role for indi-
vidual genes, particularly if consistent with genetic associa-
tion analysis (6). Historically, clinical RNA profiling stud-
ies have been small, and have relied on DNA microarrays
biased towards the 3’ end of protein-coding transcripts (21–
23), resulting in a lack of a consistent global molecular
narrative for IS in skeletal muscle. This lack of clarity re-
flects technical caveats, such as concurrent drug-treatment
(for T2DM patients), inadequate consideration of clini-
cal phenotype (23,24), as well as incomplete capture of
the transcriptome (25) – and limited statistical power (26).
More modern transcriptomic techniques, such as short-
readRNA sequencing (RNA-seq) and full transcript ‘tiling-
type’ microarrays (27) attempt to provide a complete and
accurate view of the transcriptome.While potentially more-
suited for studying cells in culture (28), RNA-seq analysis
of muscle tissue provides a skewed measure of the protein-
coding transcriptome and reproducibility in clinical stud-
ies remains surprisingly low, e.g. R2 < 0.7 (29,30) – too low
for building reproducible diagnostics. The reason for this, in
part, is that each tissue has a unique and skewed transcrip-
tome, such that the resulting RNA-seq DNA library has
an over- and -variable representation from – in the case of
muscle – contractile and mitochondrial genes (29–32). This
characteristic of the DNA library can also invalidate subse-
quent pathway analysis (33). In addition, RNA-seq profiles
of individual tissues (25,30,34,35) do not include the major-
ity of long non-coding RNAs (lncRNAs) and thus to date
at least 50% of the tissue transcriptome remains unexplored
in most clinical cohorts.
In the present study, we combined the benefits of signal-
quantification from newer generation full transcriptome
microarrays (dedicated non-competitive sequence-specific
probes), with a novel tissue-specific transcriptome assembly
approach, to over-come limitations of conventional (36) ar-
ray analysis, while providing far more extensive analysis of
lncRNAs than RNA-seq (32,37). In combination with de-
tailed phenotyping, and multiple clinical intervention stud-
ies, we identified causality-linked and dynamic components
of the metabolic disease transcriptome, providing an inde-
pendent global genomic perspective, in support of many
GWAS-MD loci, in a very resource efficient manner.
MATERIALS AND METHODS
All new arrays has been deposited at GEO (GSE104235).
The remainder of our existing array data and data used
from other labs are also available at GEO (GSE59880,
GSE47881, GSE47969, GSE48278, GSE72462, GSE73142,
GSE83619 and GSE13070). The transcriptome was defined
by the latest generation gene-chip pipeline and then uti-
lized to select the valid transcriptome from earlier gener-
ation technologies (Figure 1).
Customizing RNA expression quantification to individual tis-
sue types using a custom CDF
We hypothesized that processing of raw data from the
Affymetrix HTA 2.0 array (37) would benefit greatly from
optimization, to more efficiently detect gene expression, as
currently no account is made of study specific probe perfor-
mance. The HTA 2.0 gene-chip contains 6.9 million short
‘probes’ which are computationally combined into groups
(probe-sets) representing individual RNA transcripts (or
part of a transcript) using a ‘map’ named the chip defini-
tion file (CDF). The CDF combines probe signals irrespec-
tive of whether each probe represents an active ‘signal’ in
the tissue or cell type being profiled or not (27,36,38,39),
i.e. there is no probe-level filtering. This in turn suggests that
the present signal ‘summarization’ process is inefficient as it
will include poor performing probes and unnecessarily in-
corporate back-ground noise.More accurate determination
of transcript expression, coupled with studies incorporating
larger sample sizes should allow for the establishment of the
first robust IS RNA signature in humans.
The first step in our approach was to check the sequence
specificity of the 6.9 million probes on the HTA 2.0 ar-
ray (39). The physical design of each probe is fixed and in-
corporates the features of the reference genome used at the
time of design and thus each probe must be discarded if it
is no longer specific. We mapped probe sequences to the
latest reference genome (GRCh38 82p3) using bowtie (40)
and probes which did not map to a single genomic location
were discarded. Secondly, using the aroma.affymetrix pack-
age (41) we assessed the signal characteristics for each probe
and those probes with a low and variable signal (e.g. <10
units and co-efficient of variation >25% (for muscle)) were
removed. This process was applied to each tissue type in-
vestigated. The ∼50,000 probes that have an extreme GC
content (i.e. <20%, >80%) were also removed, because the
GC adjustment model is not linear at these extreme val-
ues. The remaining probes were combined into ‘probe-sets’,
with three probes or more, and production of this ‘exper-
iment specific’ CDF resulted in the removal of ∼3 million
probes, i.e. >40% of the original chip. Notably, this filter-
ing still allows for >200,000 transcripts (across the tissue
types examined in this project). In the present analysis, each
probe-set was based on ENSEMBL ENST definitions, and
R Bioconductor packages (42) were used to update, assem-
ble and summarize the expression data.We also included an
exon specific probe-set, based on a recent observation that
the RYR1 gene has one additional variant, which lacks a
short 15 bp exon (ENSE00002436759), that correlated with
a structural feature of muscle (‘fiber’ type) (43).
The HTA 2.0 chip processed with this new muscle CDF
yielded 169,769 ENST probe-sets (This CDF is provided
at GEO). Notably, the discarded probes (e.g. signal <10
units in this example) would have been otherwise incorpo-
rated into probe-sets that had an average signal of ∼70
units, i.e.∼7 times greater than the poor performing probes
(Supplemental Figure S1A). Use of a ‘tissue-specific’ CDF
map for quantification of the transcriptome should reduce
the influence of back-ground noise during normalization
(44). Indeed, use of this muscle CDF improved detection of
differentially expressed ’exercise’ genes ∼3–5-fold above a
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Figure 1. Analysis process. Human muscle biopsy RNA profiles came from clinical projects named STRRIDE I, II (S1–2) and III (S-PD), Meta-Predict
(MP), TIFIN, DRET, Gallagher et al. (GALL), Weigert et al. (WG), Sears et al. (SEARS), Heritage (HERTG) and IDEAL (2,22,37,38,46,50–54,,56). The
present project involved the production and analysis of 470 new samples profiled on the HTA 2.0 Affymetrix platform along with 144 new samples profiled
on the Illumina 12 platform; and 466 of our previously published (22,37,53,54) U133+2 muscle RNA profiles and literature cohorts (where appropriate
clinical data was available). The HTA 2.0 platform was processed with a 169 796 probe-set CDF (ENST), representing ∼18 000 protein-coding genes and
∼16 000 non-coding genes. The older array platform offered an opportunity to replicate protein-coding gene expression with 73 654 probe-sets (ENST)
being common to the HTA 2.0 platform. All samples and clinical data underwent a rigorous quality control check to ensure that the microarray profile
was technically robust (minimal variation in NUSE score), and the insulin and glucose values were within the operating range of the HOMA2-IR model
(10). Less than 10% of any project samples were lost to lack of one of these two components. The HOMA2-IR model requires either ELISA (more specific
insulin determination) or RIA (less specific) in p.mol.l and glucose in mmol.l and incorporates non-linear features of the glucose-insulin relationship. The
HOMA2-IR is a bona fide physiological model for peripheral insulin resistance correlating with other more precise but less physiological models (10). We
utilized the log10 transformed insulin sensitivity values (S%) as the input values for the linear covariate adjustedmodeling of peripheral insulin sensitivity. A
meta-analysis of the individual covariate adjusted P-values was aggregated using the Stouffer method and an FDR calculated (60). This process identified
∼1000 genes related to S%, of which >300 were consistently (directionality) regulated; yielding a ‘core fasting insulin sensitivity gene list’ (CORE-IS).
Having identified this reproducible set of S% genes, the causal nature of these genes during dynamic regulation of S% was investigated using clinical
intervention studies (22,37,53,54) and systems biology methodologies (data-driven co-expression analysis (77,136); protein–protein interaction databases
(137), transcription factor binding-site analysis (63) and ‘guilt-by-association’ methodologies (138)).
fixed FDR value, and demonstrated a high technical repro-
ducibility for quantifying IS related genes (Pearson coeffi-
cient of determination (R2) of 0.96, Supplemental Figure
S1B). The same tissue-specific approach was used to pro-
duce CDFs for adipose tissue and islet cell datasets (37,45)
and to process previously published HTA 2.0 muscle data.
Quality control was performed using normalized unscaled
standard error (NUSE) and principal components analysis
(PCA).
For the non HTA chip muscle data, quality control was
performed as above and<10%of previously published sam-
ples were removed (or lacked valid insulin data, see below).
Data generated on the U133+2 platform (predominately
protein-coding RNA expression) was updated with a CDF
that mapped probes to 73,654 probe-sets (ENST) in com-
mon with the muscle-specific HTA 2.0 profile. Our newly
generated Illumina Human HT-12 V4.0 array data were
processed using quantile normalization, as previously de-
scribed (46). Gene names were used to map results to those
ENST probe-sets on the HTA 2.0/U133+2 platforms (with
the highest signal being chosenwhen a gene was represented
more than once) yielding 47,216 transcripts (equating to 31
326 genes). The new Illumina array data was produced from
the ‘IDEAL’ cohort (46) and was used, along with three lit-
erature data-sets, for independent validation of the RNA
responses to clinical treatment (Figure 1). As expected the
concordance of the Illumina platform results, was less than
observed between probe-set based specific tissue confirmed
ENSTs.
Clinical samples, insulin analysis and RNA production
The present project relied on 1,012 human muscle biopsy
samples. We produced RNA from 470 human skeletal mus-
cle biopsy samples from our recent clinical studies for pro-
filing on the HTA 2.0 gene-chip (Metapredict (MP), STR-
RIDE PD (S-PF) and TIFIN, Figure 1) (47–52). Addition-
ally, we re-processed and updated 466 of our previously an-
alyzed muscle gene-chip profiles (STRRIDE I and II (S1–
2), Gallagher (GALL), IDEAL, HERITAGE (HERTG)
and Derby Resistance Training Study (DRET), Figure 1)
(22,37,53–55). A further 176 gene-chip profiles were iden-
tified from the literature (Weigert et al. (WG) and in vivo
drug treatment (SEARS) studies in Figure 1) (38,45,56).
Further, a subset of 568 muscle gene-chip profiles were
paired, from 284 individuals before and after distinct clin-
ical interventions aimed at improving IS (MP, S1–2, S-
PD, DRET, IDEAL, HERTG, SEARS and WG, Figure 1)
(38,46–48,50,52,53,56–58). Sixty percent of these samples
were not included in the baseline fasting CORE-IS anal-
ysis (see below), and thus represent entirely independent
samples from those used to discover the CORE-IS genes.
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The clinical methodologies have been extensively presented
elsewhere (22,37,38,45–48,50–54,56–58). The demograph-
ics for the subjects contributing to the present analyses are
presented in Table 1 (i.e. baseline data for IS modeling)
and Supplemental Table S1 (clinical intervention cohorts
for clinical response modeling), and Supplemental Table S3
(for the post-hoc gender comparison). Studies complied, as
per the original publications, with the 2008 Declaration of
Helsinki and were approved by the relevant ethics commit-
tees stated in each published clinical article, while all partic-
ipants gave their written, informed consent to participate.
To produce the new HTA 2.0 array profiles, RNA was
isolated using TRizol® (Life Technologies) and dissolved
in 20 l RNAse-free water, processed to single-stranded
sense fragmented DNA using the GeneChip® WT PLUS
Reagent Kit, which relies on a reverse transcription prim-
ing strategy that primes both poly-A and non-poly-ARNA.
HTA 2.0 gene-chips were processed according to the man-
ufacturer’s protocol. Fragmented (5 g) end-labeled sense
strand target cDNA was hybridized to each array and
scanned using a Gene Chip Scanner 30007G (Affymetrix
Core,MPIA/S,Denmark). From theRNAprocessed,<5%
of samples were excluded as outliers by visually evaluating
NUSE plots prior to down-stream analysis. The technical
reproducibility for detecting regulated genes was assessed
by runningRNA samples from the same subject/time-point
several months apart and examining the correlation coef-
ficient, without adjustment for any potential batch effects
(Supplemental Figure S1B). For the Illumina Human HT-
12 V4.0 arrays (Nestle Research Center, Lausanne, Switzer-
land) RNA was isolated from the skeletal muscle tissue by
using TRizol® (Life Technologies), purified using the Qia-
genRNeasyMicro kit (Qiagen, Venlo, NL,USA) andRNA
quality was checked using anAgilent 2100 bioanalyzer (Ag-
ilent Technologies, Amsterdam, NL).
There are numerous assays for insulin, each with their
own performance characteristics (59). For one-hundred and
ninety-one subjects (MP+S-PD studies) plasma insulin val-
ues (high-sensitivity, enzyme-linked immunosorbent assay
(ELISA) analysis, K6219 Dako, Sweden AB) were gener-
ated in a single core-lab. The Gallagher et al. study (22) also
utilized a high-sensitivity ELISA (Dako Sweden AB), while
the DRET study used a high-sensitivity ELISA from DRG
Instruments (GmbH,Germany). The TIFIN study used the
less sensitive radioimmunoassay (RIA, LINCO/Millipore),
as did STRRIDE I/II (Access Immunoassay System, Beck-
man). IDEAL used a RIA (Architect System, Abbott Lab-
oratories). Glucose values were determined with an oxi-
dation reaction (YSI-2300 Stat Plus, Yellow Springs In-
strument, Yellow Springs, OH). No individual insulin val-
ues were available from the published studies of Sears or
Weigert et al. (38,56). All samples/subjects from our labo-
ratories underwent updated quality control to ensure that
the array profile was technically robust and that the insulin
and glucose values were within the operating range for the
HOMA2-IR model (10).
For the cell-culture RNA studies, ∼20 000 HepG2 cells
(hepatocellular carcinoma cell line) cultured in OPTIMEM
(Gibco) were transfected (96-well plates) with 20 nM of
ASO (Integrated DNA Technologies; Supplemental data
S1) using Lipofectamine 2000 (Thermo Fisher Scientific)
for either 24, 48 or 72 h. RNA isolation and DNase treat-
ment were performed by RNeasy Mini Kit (Qiagen, USA),
in accordance to manufacturer’s instructions. RNA qual-
ity and concentrations were determined by Nanodrop 2000
(Thermo Fisher Scientific, USA). Twenty nanograms of
RNA were reversely transcribed using the High Capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scien-
tific, USA), according to manufacturer’s recommendations.
qRT-PCR (primers, Supplemental data S1) was performed
on a QuantStudio 6 Flex machine (Life Technologies) using
probe-based assays (Integrated DNA Technologies, USA).
Data was scaled to GUSB and PPIB and were expressed
relative to cells treated with a commercial control ASO.
Primary statistical analysis of gene expression
A table of normalized, log2 transformed RNA expression
values was produced for each of the studies described above.
First, we assessed the linear relationship between gene-
expression and IS (log10 of the HOMA2 model S% values,
(10)) together with age or BMI (Table 1), using analysis of
variance (ANOVA) inR (i.e. using the following linearmod-
els in R: expression∼ IS*age and expression∼ IS*BMI). A
correlation coefficient (R) and P value were calculated for
each probe-set in the two bivariate analyses per study. Sec-
ond, to produce a ‘significant’ sub-set of IS genes, we carried
out ameta-analysis of each bivariate analysis across six clin-
ical cohorts (n= 564, Figure 1), including the 73 654 ENST
probe-sets common to all chip-types (99% of which were
protein-coding), generating a false discovery rate (FDR) for
each bivariate model separately, using the Stouffer method,
in the R-packageMetaDE (60), from the ANOVAP-values.
Third, any probe-set with an FDR <10% was filtered by
univariate regression coefficient such that only those with a
directionally consistentR value across the four largest stud-
ies was retained. This resulted in the set of ‘CORE-IS’ genes
with a much lower average FDR. Post hoc analysis and
interpretation of these findings considered gene-expression
versus IS, when a covariate, e.g. BMI, was set as the primary
variable in the ANOVA model (i.e. using the following lin-
ear models in R: expression ∼ BMI*IS). Further interpre-
tation of the CORE-IS genes was based on gender depen-
dent expression using a group of males and females (n =
89 per group) where HOMA2 IR, age and peak VO2 were
balanced (Supplemental Table S3). The limma packge in R
(eBayes and lmFIT functions) was used to determine DE
with P-values adjusted using the fdr method (61).
For the ncRNAanalysis therewere a total of 282HTA2.0
profiles available. The analysis was performed as described
above (i.e. using the two bivariate models, followed by filter-
ing) for the combined S-PD and MP HTA 2.0. based stud-
ies (Figure 1, SMP, n = 191). Similar to the protein cod-
ing genes above, only ncRNAs with an FDR less than 10%
(Benjamini-Hochberg FDR using the mult-test R package)
for IS in both models and with a consistent (direction) R
value in two studies; S-PD (n = 67) and MP (n = 124) were
considered (93% were consistent). A third cohort consist-
ing of older-subjects (65–95 years) was profiled on the HTA
2.0 array (TIFIN, n = 91, Figure 1) was used to further
explore identified ncRNAs by comparing coefficients from
univariate models. 52% of the IS relationships being con-
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Table 1. Demographics of the clinical cohorts used for establishing the fasting peripheral insulin sensitivity transcriptome (2,22,37,46,50,51,53,54). The
HTA 2.0 gene-chip platform data represent entirely new data while the U133+2 gene-chip data reflects our prior data, updated and re-processed. Values
are median (range) or adjusted R2 using lm in R. VO2 peak is a measure of peak oxygen consumption or ‘maximal’ aerobic capacity, and the units are
ml min−1 kg−1, fasting glucose is m mol l−1, fasting insulin units are pmol l−1, while BMI and HOMA2-IR are unit-less and IS is percentile insulin
sensitivity calculated from the HOMA2-IR model (10). VO2 peak is a trait that is highly inherited but also influenced by behavior (intensity and volume
of physical activity)
S-PD+MP LVL-OLD GALLAG DRET S1–2
Sample size (n) 191 91 93 39 150
Platform HTA 2.0 HTA 2.0 U133+2 U133+2 U133+2
Gender (M/F) 89/103 50/41 64/29 22/17 75/84
AGE 43 (18–75) 71 (65–95) 56 (23–77) 49 (20–75) 50 (24–68)
BMI 30.5 (24.6–45.5) 26.6 (19.6–38.5) 29.6 (16.7–50.2) 25.9 (19.4–32.5) 30.1 (25.0–37.6)
VO2 peak 26.8 (13.2–46.9) - 26.0 (10.6–55.8) - 26.8 (13.2–43.9)
Fasting Glucose 4.8 (3.99–7.4) 5.5 (4.4–6.7) 5.9 (4.3–23.3) 5.6 (3.4–7.5) 5.3 (3.8–7.3)
Fasting insulin (ELISA) 57.5 (8.9–257.0) - 63.1 (10.0–251.1) 23.4 (10.5–67.6) -
Fasting Insulin (RIA) 110.8 (34.8–324.4) 54.6 (7.2–241.9)
HOMA2-IR 1.23 (0.31–9.33) 2.042 (0.67–5.96) 1.32 (0.31–21.88) 0.52 (0.23–1.63) 1.02 (0.13–4.47)
IS 81.7 (17.5–324.3) 48.9 (16.8–151.2) 75.9 (4.6–323.6) 193.1 (61.2–442.7) 98.15 (22.2–751.3)
R2 IS versus age <0.01 <0.01 0.01 0.03 <0.01
R2 IS versus BMI 0.11 0.22 0.22 0.05 0.15
R2 IS versus VO2 peak 0.02 - 0.12 - <0.01
sistent between the younger cohorts (S-PD and MP) and
this older cohort. It was expected that there would be some
differences due to both the impact of population stratifica-
tion and potential interactions between IS and muscle age
(62). The identified 86 ncRNAs completed the 332 CORE-
IS gene list that was taken forward for validation and mod-
eling.
Individual CORE-IS genes that causally regulate IS,
should respond to treatments that prevent T2DM. We uti-
lized both differential expression (DE) analysis using limma
(61) and Spearman rank correlation on data from six dis-
tinct life-style intervention studies (three independent of
the groups above, IDEAL, HERTG and WG) and sepa-
rately, one diabetes drug treatment study (SEARS). For
DE, P-values were subjected to meta-analysis and a Stouf-
fer FDR was calculated as above (60) to establish which
genes were consistently regulated across each (very distinct)
life-style intervention study. For each of four studies with
valid individual insulin measures (MP, S1–2, IDEAL and
DRET, Figure 1), log2 fold changes were calculated for the
332 CORE-IS genes and their correlation (Spearman) with
changes in IS, per subject was calculated. DE was also cal-
culated in a seventh drug-treatment study (56), where paired
t-tests were used to examine if the CORE-IS genes were
responsive to 12 weeks of treatment with a PPAR ago-
nist (The authors (56) would not provide individual clini-
cal values). Transcription factor binding site analysis was
carried out using SSA in oPOSSUM (63), with the 24,752
genes in the database as background (JASPAR CORE pro-
files (64)). Conservation cut-off was set at 0.6 and a ma-
trix score threshold of 85%, searching 10K up- and down-
stream of each CORE-IS gene transcription start site. Re-
sults were interpreted in light of the outcome found by ana-
lyzing the entire CORE-IS genes and the treatment modu-
lated DE IS list, such that enrichment over these larger lists
was considered interesting and results plotted (using Gviz,
biomaRt and GenomicRanges packages). Heat-maps were
generated using Morpheus (https://software.broadinstitute.
org/morpheus/).
Validation using published literature and GWAS analysis
To compare the CORE-IS genes identified in the present
study with GWAS-MD loci identified during the past
decade, we utilized three main resources from the GWAS
research community; the Type 2 Diabetes knowledge
portal (www.type2diabetesgenetics.org/home/portalHome)
which includes many phenotypes beyond T2DM, and
the NHGRI-EBI Catalog (www.ebi.ac.uk/gwas/home), to-
gether with gene lists presented in the most recent GWAS-
MD publications (7,16,65–76), i.e. those that recently re-
ported genetic associations for risk of development of
T2DM, insulin action (IS [insulin or HOMA IR], fasting
glucose, fasting lipids [HDL, LDL and triglycerides] and
body composition [BMI or adiposity]). The NHGRI-EBI
Catalog and published gene lists were included at the 5
× 10−8 GWAS significant threshold. The Type 2 Diabetes
knowledge portal provides three demarcations for signifi-
cance; ‘GWAS-level’ 5 × 10−8, ‘suggestive association’, 5 ×
10−4 and ‘red’ indicating that the loci was non-significant
for any GWAS phenotype. A systematic literature review,
whereby the CORE-IS gene name was searched with and
without the terms; ‘insulin’, ‘diabetes’ or ‘obesity’ (Pubmed,
June 2017) followed by an extensive assessment of whether
a direct biochemical interaction had been reported, was
recorded (see below and Supplementary files).
Gene-network structure and pathway analysis
As we produced continuous quantitative data, for gene ex-
pression, from significantGWAS loci, we could utilize prob-
abilistic network analysis incorporating inferred causal rela-
tionships betweenmolecules and disease (4,5) to explore the
biology of IS. The R-package MEGENA (77) was used to
identify network structures within the largest and most de-
tailed sub-group (SMP, n = 191, HTA 2.0 data and single-
core high-sensitivity insulin assay). Our aim was to char-
acterize the interacting components of the CORE-IS gene-
list (78), determine if they formed significant sub-networks
using strict thresholds (FDR < 1% for Spearman correla-
tion; P < 0.01 for module significance and P < 0.01 for
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network connectivity; and 1000 permutations for calculat-
ing FDR and connectivity P-values). Stability of individual
sub-clusters of a network was assessed based on the impact
of a data-split on compactness on a parent cluster, versus
the impact of randomly permuting or inserting nodes. Net-
work plots were produced using Fruchterman–Reingold
force-directed plotting (77) within MEGENA. Each pre-
sented significant network was populated with visual iden-
tifiers (color-coded circles) for GWAS-MD loci.
Interpretation of each significant network or module was
carried out in several ways. Firstly, using NetworkAna-
lyst (http://www.networkanalyst.ca/) and the IMEx Inter-
actome curated protein–protein interaction database (79).
Each gene list was analyzed using default settings and min-
imum order network was chosen for gene ontology analy-
sis (GO, Biological Process, GOBP). Enriched GOBP, with
FDR < 1 × 10−5, were considered of interest. For each
analysis, the result was confirmed after removing Ubiq-
uitin because we noted it appeared as the highest ranked
gene (‘betweeness’ score) in every protein interactome, re-
gardless of the input gene ID list (probably reflecting tech-
nology bias, (33)). To further describe each network mod-
ule, summary statistics were calculated for the proportion
of ncRNAs, number of positively associating IS genes, the
sub-phenotypes underlying the link with the GWAS-MD
loci, and the number of genes responsive to interventions.
Finally, for significant modules (e.g. treatment respon-
sive genes) TF analysis (as above) and guilt-by-association
(GBA) analysis, was performed (80). For the latter, the
’Genefriends’ human transcriptome database (81) was used
to help locate additional links between CORE-IS genes,
pathways and metabolic disease GWAS loci.
RESULTS
A total of 326 pre-intervention new muscle samples were
profiled on the HTA 2.0 gene-chip (MP, S-PD and TIFIN,
Figure 1). We updated the processing of 424 of our pre-
viously published muscle gene-chip profiles (Affymetrix
U133+2 gene-chip [S1–2, GALL,DRET andHERTG, Fig-
ure 1 (2,22,37,46,50,51,53,54)] and several literature-based
cohorts (38,53,56).
Identification of a robust set of genes which covary with fast-
ing peripheral insulin sensitivity
To produce a high-stringency set of IS related protein cod-
ing genes, we performed meta-analysis of 564 samples orig-
inating from these six independent cohorts (73,654 ENST,
on HTA 2.0 arrays (two studies) and U133+2 arrays (four
studies), Figure 1). Each study had a comparable distribu-
tion of IS (Supplemental Figure S2) and clinical charac-
teristics (Table 1). The P-values derived from the relation-
ship between RNA abundance and IS in each of six studies
were subjected to meta-analysis using the Stouffer method
(60) identifying 1005 protein coding genes (mean FDR =
1.7%). To be considered further, the R value for RNA ex-
pression versus fasting IS had to have a consistent direction-
ality across the four largest cohorts. This led to the iden-
tification of 246 protein-coding genes, forming part of the
CORE-IS gene list (Supplemental data S2).
The majority of the detectable ncRNAs in muscle were
classed as ‘antisense’ or ‘lncRNA’ molecules (Figure 2A).
To examine which lncRNAs were related to IS, we utilized
three sub-cohorts of muscle data produced on the HTA 2.0
array (Table 1, n = 282) and found 86 ncRNA associated
with IS (Mean FDR = 5%). Half of these were classed as
‘antisense’ or ‘lncRNA’ molecules and were largely consis-
tently expressed in S-PD and MP cohorts, (Figures 1 and
2B); but less so in the cohort of older subjects (TIFIN, n =
91). To compare the expression pattern of IS-related muscle
ncRNAs to other T2DM relevant human tissue-types, we
produced tissue-specific HTA 2.0 CDFs for adipose tissue
(37) and human pancreatic cells (45). The majority of the
muscle IS-related lncRNAs were expressed at comparable
levels in human adipose and islet-cells (Supplemental data
S3, and Figure 6 below), so they may plausibly impact on
insulin biology and metabolism across multiple organs.
Approximately half of the IS lncRNAs had cis-expressed
transcripts, most of which were protein-coding (Supple-
mental data S3). Approximately 30% of these lncRNAs
demonstrated a sizeable positive or negative co-expression
pattern, across 191 samples, with their cis protein cod-
ing partner; these included LINC-PINT, HOXB-AS3,
TMEM191A and PRKCQ-AS1 (Figure 2C), a natural anti-
sense for the diabetes drug-target PRKCQ (codes for PKC-
) (82–85). We initially sought to study three antisense
lncRNAs in vitro: PRKCQ-AS1, NPSR1-AS1 and RP11–
582J16.4 (AC037459.2). All were robustly expressed in both
normal hepatocytes and HepG2 cells (insulin target cells)
but the partner of NPSR1-AS1, NPSR1, was not detected
in vitro and thus only PRKCQ-AS1, and AC037459.2 were
studied. For each lncRNA, four phosphorothioate anti-
sense oligonucleotides (PS-ASO) were designed. The PS-
ASOs did not reduce the expression ofAC037459.2. All four
PS-ASO targeting PRKCQ-AS1, however, provided ∼50–
60% knockdown in the HEPG2 human liver cell line, result-
ing in increased expression from the cis-expressed protein-
coding gene, at the time-points examined (24–72 hours; Fig-
ure 2D). Given the role PRKCQ plays in insulin signaling,
and the extensive complexity of the transcripts expressed
from the PRKCQ loci, detailed studies are merited to ex-
plore the interaction with each splice-variant and subse-
quence impact on cell metabolism and signaling.
CORE-IS list is composed of genes with biochemical and ge-
netic links with type 2 diabetes
An extensive literature review, searching for a substantial
link between the CORE-IS genes and insulin, diabetes or
obesity provided overwhelming support for the validity of
our ENST-based analysis (Table 2; for the citations see Sup-
plemental Table S2 within the supplemental materials docu-
ment). We subsequently established that this subset of liter-
ature supported IS genes demonstrated the strongest uni-
variate linear relationship with IS, as a sub-group of all
CORE-IS genes (P < 0.03, Bonferroni corrected t test). To
further explore the CORE-IS list we considered the hun-
dreds of genomic loci that have been linked to the risk of
developing T2DM or associated with variation in insulin,
BMI or glucose homeostasis (7,12,72–76,86,16,65–71). For
the majority of these loci it remains unclear which gene
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Figure 2. The human muscle non-coding RNA transcriptome: relationship with insulin sensitivity. (A) The non-competitive nature of RNA quantification
and tissue configured CDF for the HTA 2.0 microarray facilitated the first detailed and quantitative view of long non-coding RNA molecule expression
in human skeletal muscle in vivo (>20 000 ENST representing 16 223 genes (ENSG)). The majority of non-coding RNAs (ncRNAs) identified in human
muscle were classed as either ‘anti-sense’ molecules or long non-coding RNA (lncRNA). (B) We utilized three clinical cohorts (n = 282), with varying
ranges of chronological age, to examine which ncRNAs were related to insulin sensitivity (IS). Eighty-six long ncRNA associated with IS, the majority (43)
being either antisense or lncRNA (Figure 2B, See Supplemental data S3). The vast majority of these were also expressed in adipose and pancreatic cells (in
vitro beta cells, Supplemental data S3) indicating they could influence insulin biology across multiple organs. The relationship between each ncRNA and
IS was largely consistent in the three sub-groups, with greater variability noted among the oldest subjects, which may reflect population stratification (62).
LncRNAs like NEAT1 and MALAT1 were very highly expressed and regulate gene expression via interactions with chromatin (139), while the majority
of the IS related ncRNAs were expressed at a level similar to coding mRNA. (C) Four examples of lncRNA molecules related to fasting IS and how
they co-vary with their cis expressed protein-coding transcript in vivo (n = 191, younger samples). The protein-coding transcripts were not themselves
significantly correlated with IS. (D) Human HepG2 cells (hepatocellular carcinoma cell line) were transfected with 20 nM of phosphorothioate antisense
oligonucleotides (PSASO, one control ASO and four different ASO targetingPRKCQ-AS1) in triplicates, and expression ofPRKCQ-AS1 (A) andPRKCQ
(B) wasmeasured by quantitative real-time PCR.ASO-induced knockdownwas statistically significant (P< 0.01). Values were normalized toGUSB/PPIB
and expressed relative to levels in cells treated with control ASO. Values are mean ± SEM.
(or genes, given the potential for linkage disequilibrium
(LD)) represent the causal link (14). Overlaps between the
CORE-IS gene list and these GWAS-MD loci would fur-
ther substantiate our analysis but more importantly help
identify which gene underlies the reported genetic associa-
tion. Indeed, at least 45 of the 332 CORE-IS genes originate
from GWAS-MD loci at a genome wide significant level
(P < 5 × 10−8), while a further 180 have suggestive associ-
ations according to www.type2diabetesgenetics.org/home/
portalHome (see Materials and Methods, Table 2 and Sup-
plemental data S4). The majority of genes linked to either
risk of T2DM or risk of Obesity, with a smaller number to
more discrete phenotypes (fasting insulin, fasting glucose
or circulating lipids––reflective of smaller GWAS samples
and/or phenotypes with greater random and technical er-
ror) (Figure 3A).
Substantial differences in age, aerobic fitness etc. be-
tween T2DM cases and controls, especially in combination
(23,24,87), will yield gene expression differences inappro-
priately assigned to T2DM or IR, as well as potentially ob-
scuring genuine differences. For some, but not all, of our
cohorts, age or BMI modestly covaried with IS (Table 1).
When examining the results of the ANOVA analysis after
first considering the co-variate (‘adjusting’), there was no
overall impact of Age on IS gene selection except for some
slight reductions the FDR achieved for somemitochondrial
genes (Figure 3B). Notably, there was no IS dependent ex-
pression pattern for oxidative phosphorylation (OXPHOS)
genes regardless of which ANOVA model was used (Fig-
ure 3B). In contrast, when BMI was utilized to ‘adjust’ the
ANOVAmodel for IS, a number of CORE-IS genes were re-
moved (Figure 3C) while an additional 33 genes passed the
FDR threshold (Supplemental data S4), of which seven oc-
curred at GWAS significant loci for obesity or blood lipids,
but none for the other phenotypes. The genes lost from the
CORE-IS, when the ANOVA model assigned covariance
between IS and BMI to the covariate, included nine genes
fromObesity risk loci, eight genes fromT2DM risk loci and
two others. This demonstrates that neither approach to lin-
ear modeling is fully compliant with the complexity of the
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Table 2. CORE-IS genes with established links with insulin biology or metabolic disease
Gene ID
[RNA] 
relaonship 
with IS
Published 
Biochemical 
relaonship
T2DM Portal Evidence System 
(Green=5x10-8, Yellow=5x10-4)
GWAS Signiﬁcant 
(GWAS Catalog/Arcles) Gene ID
[RNA] 
relaonship 
with IS
Published 
Biochemical 
relaonship
T2DM Portal Evidence System 
(Green=5x10-8, Yellow=5x10-4)
GWAS Signiﬁcant 
(GWAS Catalog/Arcles)
AASS posive > beer S% WC MAGI3 negave IS, TG
ABCG1 posive > beer S% IS, Adiposity MAPKAP1 negave < beer S% WHR Obesity
ABHD2 negave < beer S% T2DM, LDL MAPRE3 negave FG, TG T2DM
ACADL posive > beer S% MAST3 negave BMI, WC, WHR
ACOT11 posive > beer S% IS, T2DM, BMI, LDL MAT2B posive T2DM, LDL, Adiposity
ACSS1 posive > beer S% BMI MCC negave T2DM, IS, HDL, TG, BMI, WC, LDL, HOMA-B T2DM, Obesity, IR, Lipids
ADPRHL1 negave MCCC1 posive > beer S% BMI
AGL negave < beer S% TG ME2 negave < beer S% TG
AKR1B15 negave WHR MRC2 negave T2DM, BMI, IS
ALDH1L1 posive > beer S% BMI, LDL, WHR, Adiposity MROH7 posive WC
ALDH1L2 negave BMI, WC MROH7-TTC4 posive T2DM
ALDH6A1 posive > beer S% MSRB3 negave WHR, WC T2DM
ANKRD50 negave T2DM MSTN negave < beer S% BMI
ANKS1B negave IS, T2DM, BMI, FG, LDL Obesity MTDH negave T2DM, Adiposity
ASCC1 negave IS MTF2 posive HDL (LDL, WHR) Lipids
ATAD2 posive T2DM, WHR MTPN negave Obesity
ATP1A1 negave < beer S% HDL MTRF1 negave T2DM
ATP1B3 negave HDL MUSK negave T2DM, IS, WHR, Adiposity
ATP2A2 posive BMI MYBPC2 negave BMI
B4GALT6 negave < beer S% IS MYL1 negave IS
BCL2L11 posive BMI, T2DM, WHR, Adiposity MYL12A posive IS
BDH1 posive > beer S% IS, T2DM, BMI MYLK4 negave IS, Adiposity
BRD8 posive > beer S% T2DM, BMI N4BP2L1 posive T2DM, WC, HDL, LDL, BMI
C15orf41 posive IS, BMI, WC NCAM1 negave T2DM, IS, FG, BMI, HOMA-B Obesity
C1orf158 negave Lipids NDUFAF5 negave < beer S% T2DM, LDL, Adiposity
CAB39L negave BMI, WHR, WC NETO2 negave IS
CACNB1 negave T2DM NIN negave BMI, TG, Adiposity
CALM1 negave < beer S% IS NSF negave < beer S% BMI, WC, WHR, pro-insulin
CARNS1 negave < beer S% BMI, TG NUCB2 negave < beer S% WC (BMI, T2DM, WHR) T2DM, Obesity
CBX7 posive WC NUP210 posive BMI, WC, WHR, HC
CCDC25 negave WC OARD1 posive HC
CCDC69 negave IS, T2DM, TG, LDL OSBPL6 negave T2DM, WC, WR, Adiposity
CCNB1IP1 posive IS, T2DM PARK2 negave < beer S% BMI (T2DM, TG, IS, LDL, WC, Adiposity) Obesity
CD151 negave HOMA-B PCYT2 posive > beer S%
CD38 negave < beer S% T2DM PDHX negave < beer S% WC
CDK14 negave < beer S% IS, BMI, T2DM, WHR PDLIM7 negave < beer S%
CDK2AP1 negave < beer S% HDL, T2DM, LDL T2DM PGK1 negave < beer S%
CEBPD posive > beer S% T2DM PGM2 negave < beer S% IS
CEBPG negave IS, WC, HDL, WHR T2DM PHKB negave < beer S% BMI, WHR
CERS6 negave < beer S% FG, (BMI, T2DM) FG, (BMI, T2DM) PKM negave < beer S% BMI, TG
CLIP4 posive BMI PLXDC1 negave T2DM, LDL
COL15A1 negave TG, WC PON2 negave < beer S%
COL4A3BP posive BMI, LDL Obesity PPM1L negave < beer S% BMI, T2DM
COL5A2 negave IS, HDL PPP1R3B negave < beer S% T2DM, BMI, TG, WC, LDL, WHR T2DM, IR, Lipids
COL6A1 negave T2DM, WHR, FG, LDL Obesity PPP2R5C negave < beer S% IS, T2DM, BMI, WC, WHR
CORO1C negave < beer S% LDL PRDX6 posive > beer S%
CRBN posive > beer S% T2DM PRKAG3 negave < beer S% Obesity
CTH posive > beer S% PRRX1 posive LDL, WC, WHR Obesity
CTSF posive IS PRSS42 posive HDL
DAAM1 negave T2DM, BMI, Adiposity, WHR T2DM RAB29 negave n/a Obesity
DAPK1 negave IS, HOMA-B, TG, WHR, Adiposity RAB30 negave T2DM, IS
DAZAP1 posive T2DM (WC) T2DM (WC) RAB40C posive FG, WC, HC
DDR1 posive > beer S% T2DM, LDL, TG, Adiposity T2DM RAPH1 negave < beer S% T2DM, LDL
DHRS7 negave < beer S% BMI, LDL RCBTB1 negave IS, BMI
DHTKD1 posive > beer S% TG, WHR T2DM RDH10 negave < beer S%
DPYSL3 posive T2DM RND3 negave < beer S% T2DM, LDL, BMI, WC T2DM
E2F3 negave T2DM, BMI, LDL, WC T2DM RNF10 negave < beer S% BMI, WC
ECT2 negave BMI ROBO1 negave < beer S% IS, BMI, WHR, WC, Adiposity, LDL, HDL
EDEM3 negave T2DM RXRG negave < beer S%
ELP2 posive TG, HDL, FG, WHR SATB1 posive WHR, WC
EML4 negave T2DM (BMI, LDL, IS, FG, WC) T2DM (BMI, LDL, IS, FG, WC) SEC61A1 negave < beer S%
EPDR1 negave IS SEPT11 negave < beer S% FG, BMI, Adiposity
ERBB3 negave < beer S% WC SESN1 posive T2DM, LDL
EZH1 posive WHR SESN3 negave < beer S% LDL
FAM118B negave LDL SETDB2 negave < beer S% IS
FAM160A1 posive IS, Adiposity SFRP4 negave < beer S% IS, WHR, WC
FARP2 negave TDM, HDL SGCG posive T2DM, IS, LDL, TG, WHR T2DM
FAT1 negave IS, LDL, BMI Obesity SGMS2 negave < beer S% T2DM
FERMT2 negave IS, FG, BMI, Adiposity SH3PXD2A posive T2DM, IS, Adiposity, WC
FOXP2 posive T2DM, BMI, IS, Adiposity, WHR Obesity SH3RF2 negave T2DM, BMI, WHR
FRMD3 negave < beer S% T2DM, HDL, BMI, LDL SHISA2 negave HC
G0S2 negave < beer S% FG SHISA4 negave BMI (T2DM, IS) BMI (T2DM, IS)
GADL1 negave IS, BMI, LDL, WHR T2DM SLC16A10 negave < beer S% T2DM, BMI
GCLC posive T2DM, IS, BMI, WHR, TG SLC27A1 posive > beer S%
GLUL posive > beer S% SLC43A1 posive > beer S% LDL, WC, WHR
GPAT3 posive > beer S% n/a SLC4A4 negave T2DM, IS, BMI, WC
GPD1 negave < beer S% WC SMIM8 posive LDL
GRB14 negave T2DM, IS, LDL, HDL, TG, WHR T2DM, IS, LDL, HDL, TG, WHR SMTNL2 negave BMI
GRIA3 negave TDM, Adiposity SOS2 negave IS, Adiposity
GSR negave T2DM, IS, HOMA-B SPARC negave < beer S% WHR
HBP1 posive > beer S% TG, WC SSX2IP negave FG Obesity
HEXIM1 negave < beer S% Adiposity STK38 negave T2DM
HNRNPD posive WC STK38L negave BMI, LDL, WHR
HOMER1 negave < beer S% IS TACC2 posive T2DM, IS, BMI, WHR, WC, Adiposity
HOXB-AS3 posive Obesity TANC2 negave T2DM, BMI, LDL, WC, WHR
IGF1R posive > beer S% T2DM, BMI, WC, FG, LDL, WHR Lipids TPRXL posive T2DM, Adiposity
ING5 posive WHR, WC TSPAN15 negave WHR T2DM
INSR posive > beer S% TG (T2DM, BMI, HOMA-B, HDL) T2DM, Obesity, IR, Lipids TSPAN3 negave T2DM T2DM
ITIH5 negave < beer S% T2DM, WHR, FG TSPAN9 negave BMI, HDL, WHR, Adiposity
KCNN3 negave < beer S% T2DM, IS, WC TTC8 negave T2DM
KIAA1109 posive T2DM, IS, BMI, WHR, TG TUBGCP4 posive IS, TG, BMI, T2DM
KIAA1841 posive T2DM TULP4 negave T2DM, IS, WC
KLF12 posive T2DM, IS, BMI, FG, LDL, WHR, TG T2DM, Obesity UBE2G1 posive HDL
KLF15 posive > beer S% UBE4A posive T2DM, HDL
KLHL2 negave T2DM, WHR UNKL posive IS, WC
KLHL31 negave T2DM, WHR, Adiposity, HOMA-B Obesity USP25 posive FG, WC, HC
KPNA2 negave T2DM, TG VCL negave T2DM, BMI, Adiposity
KPNA5 negave IS, BMI, HOMA-B VPS8 posive FG
LAMB2 negave IS WWOX negave T2DM, IS, FG, TG, BMI, WHR, WC, Adiposity T2DM, Obesity
LDHA negave < beer S% FG, WHR XPO4 posive T2DM, HDL, HC
LDHB posive > beer S% T2DM, WC ZEB1 negave WC
LGALS1 negave < beer S% ZFAND5 posive WHR
LGR5 posive > beer S% T2DM, WC T2DM ZMAT3 negave T2DM
LIN52 posive T2DM, BMI ZMYM2 negave WHR
LPL posive > beer S% TG, HDL (T2DM, LDL) T2DM, Obesity, IR, Lipids ZNF274 posive Adiposity Lipids
LRRFIP2 negave FG ZNF282 posive WC
LRRN3 negave T2DM, Adiposity
Two-hundred and 13 genes from332 have prior linkswith T2DMphenotypes (54GWAS-Significant for T2DMphenotypes, 82with functional/biochemical
studies linking to insulin resistance, biology or metabolic disease and 180 GWAS ‘suggestive’ associations (5x10-4). Adiposity = linked to adipose mass
phenotype. BMI = Body mass index. FG = Fasting glucose. HDL = HDL cholesterol. IS = measure of insulin sensitivity. LDL = LDL cholesterol.
Pro-insulin = pro-insulin levels. TG = Triglycerides. WC = Waist circumference. WHR = Waist-to-hip ratio. T2DM = Risk for T2DM. () = at the
lower significance. Data resources are: http://www.type2diabetesgenetics.org/home/portalHome, https://www.ebi.ac.uk/gwas/home and Pubmed (June-July
2017).
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Figure 3. RelationshipwithGWAS-MD loci and the impact of covariatemodeling on insulin sensitivity relationship with gene expression. (A) Themajority
of CORE-IS genes located at genome wide significant metabolic disease loci (GWAS, 5 × 10−8), were related to either ‘risk of developing T2DM’ (24) or
‘Obesity/BMI’ (22), partly reflecting the greater number of such loci, over those known to influence fasting insulin or glucose. See Table 2 for details of
∼180 genes; for what the Diabetes consortium defined as marginal GWAS loci (5 × 10−4). (B) When the relationship between IS and RNA is studied using
ANOVA and a covariate, e.g., age or BMI, the model yields P-values for both variables, where the outcome depends on the order in the linear model and
the inter-relationship between IS and Age/BMI. The log10 false discovery rate (FDR) values (using the Stouffer method and a calculated FDR (60)) are
plotted for three gene-sets (CORE-IS ENST, mitochondrial located genes and the Mootha et al. (26) defined OXPHOS gene-set) from the two different
models, IS*age and age*IS. As can be seen, the vast majority of CORE-IS genes remain significant when adjusted for age (i.e. age*IS) as compared to
IS*age, but with a small systematic loss in statistical significance. There are only two significant OXPHOS genes, one down-regulated with better IS, and
one of which is related to an interaction with age. (C) The log10 false discovery rate (FDR) values are plotted for three gene-sets (the CORE-IS ENST,
mitochondrial located genes and the OXPHOS gene-set) from the two different models, IS*BMI and BMI*IS. As can be seen, there is a systematic loss in
statistical significance when BMI is adjusted for (BMI*IS) in the model as compared to IS*BMI. Approximately 38% of the CORE-IS protein coding genes
FDR-values are no longer significant when BMI is considered first, in the ANOVA Type I model, while a further 33 are identified, with a proportionate
gain in new GWAS-MD loci (mainly for BMI or Obesity) when this alternate model is used.
biological relationship between BMI and insulin as the sec-
ondANOVAmodel enriched the IS correlated gene list with
genetic loci associated with obesity rather than insulin. Fi-
nally, the lack of any relationship between OXPHOS gene
expression and IS (26) supports recent mechanistic studies
dissociating OXHPOS status and insulin signaling (88). We
did, however, observe the expected univariate correlation of
OXPHOS genes with chronological age and aerobic capac-
ity.
Response of the CORE-IS genes to therapeutic clinical inter-
ventions
Supervised exercise-training (with or without calorie re-
striction) can improve IS in humans, and is considered a pri-
mary prevention strategy for reducing risk of T2DM (89).
Thus, if the CORE-IS genes are responsible for regulating
peripheral insulin sensitivity, treatment should cause dif-
ferential expression (DE) of the CORE-IS RNA in mus-
cle. Six independent life-style intervention studies (Supple-
mental Table S1) were used for meta-analysis and an FDR
was calculated (60) (Figure 1)). We found that at least 135
(>40%) of the protein-coding IS-CORE genes were differ-
entially regulated in the clinical intervention studies (meta-
analysis FDR < 5%) and in a consistent direction (Figure
4A, Supplemental data S5 and Supplemental Figure S3).
Further, in a seventh study where 12 weeks of PPAR ago-
nist drug-treatment improved IS (56), 70 protein coding IS
genes were DE (P < 0.05 using a t-test, Supplemental data
S5, i.e. ∼29% of the detected CORE-IS genes). In the two
clinical intervention studies where HTA 2.0 array-data were
available, 20 of the CORE-IS ncRNAs were DE by treat-
ment (Supplemental data S5). Thus, there is substantial ev-
idence that the CORE-IS genes are regulated by life-style
interventions aimed at treating and/or preventing T2DM.
While DE analysis further supports a direct role for
the CORE-IS genes regulating IS in humans, the most
important regulators of IS are likely to be regulated in
proportion with the change in clinical status. Individual
pre- and post-intervention IS values were available for
four of the intervention studies. Spearman rank correla-
tion coefficients were calculated for delta CORE-IS gene-
expression versus delta IS, identifying 16 genes consis-
tently regulated in proportion with the clinical improve-
ment in all four independent studies (Figure 4B, cumula-
tive binomial probability, P = 0.0000053) and, critically,
in a directionally consistent manner with the fast IS re-
lationship. These 16 genes segregated into two clusters,
one positively (DHTKD1, SLC43A1, PCYT2, MCCC1,
SGCG, ECHDC3, ALDH6A1, SMIM8 and OARD1) and
the other negatively associated (PGM2, RND3, G0S2,
AGL, TSPAN9 and KPNA2) with improvements in IS.
PPAR agonist drug-treatment collectively tended to influ-
ence these 16 genes more than the average across the entire
CORE-IS gene list (medianP= 0.07 versusP= 0.18). Con-
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Figure 4. Treatment-responsive insulin-sensitivity genes. Supervised exercise-training (with or without calorie restriction) can improve peripheral IS (48,50)
and is considered the primary tool to reduce the risk of developing type 2 diabetes. If the Core-IS genes regulate IS they should respond to clinical inter-
ventions and do so in a manner consistent with the observed improvement in IS. (A) Differential gene-expression for 332 Core-IS genes was calculated,
across six intervention studies (three were independent of the baseline IS analyses), P-values aggregated using the Stouffer method; and a false discovery
rate (FDR) was calculated (60). Approximately 40% of genes were differentially regulated (FDR< 5%) by treatment, and critically in a direction consistent
with their observed relationship with fasting IS, and despite the highly divergent nature of the exercise/life-style modification interventions. (B) The rela-
tionship between the magnitude and direction of CORE-IS gene expression and the magnitude and direction of IS responses to clinical intervention were
calculated using Spearman rank correlation. Individual HOMA2-derived IS were not available for the HERTG (insulin assay) or the Weigert et al. (38)
(data availability) studies. This lead to the identification of a subset of 16 genes, from ∼250, that were consistently correlated with change in IS, in all
the four independent studies. The 16 genes segregated into two subsets––one (DHTKD1, SLC43A1, PCYT2, MCCC1, SGCG, ECHDC3, ALDH6A1,
SMIM8 and OARD1) positively associated with improvements in IS, and one (PGM2, RND3, G0S2, AGL, TSPAN9 and KPNA2) negatively associated.
Many CORE-IS genes, especially belonging to network 1 and 2 (Figure 5 and Table 3) were also, on average, DE following 3 months of a PPAR agonist
(Supplemental data S5, (56)) - unfortunately no individual IS values were accessible from the authors to study the quantitative correlative relationship with
IS.
served transcription factor (TF) binding-site analysis (63)
identified RREB1 and INSM1 binding-sites (Z-score 13.9
and 11.6) in the 16 genes activated in proportion to the im-
provement in IS (Supplemental Figure S4). These binding
sites were not enriched in the (larger) set of ‘all exercise-
responsive’ CORE-IS genes nor in the entire 332 Core-IS
gene list (Supplemental data S6), suggesting a more spe-
cific relationship with these 16 IS genes (’Delta-IS’). In the
two studies examining ncRNAs, some changed in propor-
tion to clinical improvements (e.g.RORA-AS2, SNORA70,
AL136979.1, PRKCQ-AS1, SNORD83A, ATP13A4-AS1
and NPSR1-AS1). In each case the pattern of change was
positively correlatedwith changes in fasting IS (Supplemen-
tal data S6).
The treatment regulated CORE-IS genes can be further
investigated by ‘guilt-by-association’ (GBA) analysis (80),
relying on completely independent data (81). We tested the
hypothesis that the nine CORE-IS genes positively corre-
lated with a change in IS in intervention studies and the
transcription-factors distinctly associated with this subset
of Delta-IS genes, could regulate an additional ‘layer’ of
genes responsible for regulating IS. Multi-tissue (81) anal-
ysis identified 52 genes (P < 1 × 10−6) co-expressed with
Delta-IS genes (Supplemental data S7). This 52-gene sub-
set was 77-fold enriched for branched-chain amino acid
(BCAA) catabolic genes (P< 1× 10−5) located in the mito-
chondrial matrix, and included nine additional GWAS-MD
loci beyond the 45 already in the CORE-IS list (ALDH2,
C3, CD36, HNF4A, HMGCS2, KHK, IDH2, RREB1 and
SERPINA6 (65)). The cluster of genes covarying with the
7 negatively correlating Delta-IS genes contained a fur-
ther two GWAS-MD loci (SLC2A4 and PPARG). Thus,
both theGBA analysis and the CORE-IS analysis identified
genes linked to GWAS-MD and in particular, catabolism of
BCAAs (valine, leucine and isoleucine) and aromatic amino
acids (phenylalanine and tyrosine). Indeed, studies from
1960 onwards have identified associations between circulat-
ing levels of BCAA and aromatic AAwith IR (47,90).More
recently, pre-clinical studies identified that catabolism of va-
line may act as a signal to promote muscle lipid uptake (91).
Here, we show that altered muscle gene expression in the
AA catabolic pathways occurs in the absence of any system-
atic loss of mitochondrial OXPHOS gene expression (Fig-
ure 3B).
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Table 3. Summary of CORE-IS RNA networks
Network Size Relation to IS Biotype P–P interaction profile GBA transcriptome profile*
1 Figure 5A 87 64% negative 13% ncRNA Insulin receptor signaling pathway
(FDR<1 × 10−5 6.7 FE); interaction
with host (FDR<1 × 10−4, 4.0 FE)
Extracellular matrix
organization (FDR<1 ×
10−32, 5.3 FE)
2 Figure 5B 81 75% negative 22% ncRNA Positive regulation of
nucleobase-containing compound
metabolic process (FDR < 1 × 10−8, 3.0
FE); positive regulation of metabolic
process (FDR <1 × 10−7, 2.3 FE)
Muscle filament sliding
(FDR < 1 × 10−35, 17.1 FE)
3 Supplemental
Figure S5
83 66% negative 20% ncRNA Interaction with host (FDR < 1 × 10−7,
6.2 FE); enzyme linked receptor protein
signaling pathway (FDR < 1 × 10−7, 3.6
FE)
n/s
4 Figure 6 49 16% negative 70% ncRNA Viral reproductive process (FDR < 1 ×
10−48, 5.5 FE); translational initiation
(FDR < 1 × 10−37, 8.7 FE)
n/s
5 - 32 13% negative 19% ncRNA Protein catabolic process (FDR < 1 ×
10−12, 3.1 FE)
n/s
MEGENA planar filtered networks were produced using 191 HTA 2.0 gene-chip samples (See methods). protein–protein interaction analysis was carried
out using www.networkanalyst.ca and the IMEx Interactome (79). The guilty-by-association analysis (80) used GeneFriends (81). *when using a database
for GBA analysis, it is expected that co-correlation will occur between gene expression from the input tissue type (regardless of physiological status), and
with genes in that tissue type within the data-base. This is a type of sampling bias that skews Gene Ontology analysis when inputting large lists from distinct
tissues (in this case skeletal muscle).
Networks analysis reveals the inter-relationship between the
GWAS-MD enriched IS genes
We next examined if the CORE-IS genes formed robust
networks, and if protein–protein (P–P) interaction analy-
sis, relying on further independent data (79), would demon-
strate that each ’gene’ network contained proteins known
to physically interact (78). Typically, genes from validated
GWAS loci are used to weight nodes within gene-expression
networks (5), however, in this case we used the identified
RNA-RNA network relationships to gain insight into how
GWAS-MD loci genes may interact, within the quantitative
and continuous framework of RNA abundance. Moreover,
this strategy allowed us to associate ncRNAs (mostly of un-
known function) with specific proteins and hence biochemi-
cal pathways. UsingMEGENA (77) we identified seven dis-
crete planar filtered networks (Table 3) (n= 191, FDR<1%
for Spearman correlation; P< 0.01 for module significance
and P < 0.01 for network connectivity).
The largest discrete planar filtered network contained
87 CORE-IS genes (13% ncRNA) with an enrichment
in genes negatively co-varying with in vivo IS (64%, cf
30% of all CORE-IS genes demonstrated a negative co-
variation with IS, Table 3 and Figure 5a). Protein–protein
interaction analysis characterized the function of the
protein-coding members of a minimum network (79) as
‘hormone signaling including Insulin’ (Table 3); and in-
cluded the insulin-receptor, itself. This network contained 7
(ALDH6A, DHTKD1, KPNA2, MCCC1, PCYT2, PGM2
and RND3) out of the 16 CORE-IS genes regulated pro-
portionately to changes in IS across four clinical stud-
ies. Remarkably, ∼50% of these protein-coding genes were
also DE following anti-diabetes drug-treatment (56); in-
cluding ALDH6A DHTKD1, PCYT2 and RND3 (this
compares with <5% of the transcriptome responding
to drug -treatment (56)). A module centered around
ALDH6A (encoding methyl-malonate semi-aldehyde de-
hydrogenase), a protein which catabolizes valine. Closely
co-expressed with ALDH6A, was the insulin-receptor, and
MCCC1 (methyl-crotonoyl-CoA carboxylase 1, which is in-
volved in leucine catabolism (92,93)), and AASS (alpha-
aminoadipate delta-semialdehyde synthase, which catabo-
lizes lysine). DHTKD1 (dehydrogenase E1 and transketo-
lase domain containing 1) also catabolizes amino-acids, as
does ALDH1L1. In each case, greater (BCAA catabolis-
ing) gene expression was associated with better IS. Seven
members of the network overlappedwith genes fromGWAS
significant Obesity loci (Figure 5A, brown circles) and five
were from GWAS significant T2DM-risk loci (blue circles).
Many of the remaining members of the network are in-
volved in metabolism; with clear roles in T2DM (glycoly-
sis or glycogen break-down, LDHB or PGM2). Thus, the
first discrete network is strongly modulated by all clini-
cal interventions, and biochemically linked to amino-acid
catabolism.
The second discrete network (81 genes) was composed
of 22% ncRNA (Table 3 and Figure 5B) and was predom-
inantly negatively associated with IS (75%). A third of the
protein-coding components were responsive to PPAR ag-
onist drug-treatment (56); P–P interaction analysis indi-
cated the network included genes involved with ‘positive
regulation of metabolic process’ (FDR < 1 × 10−7, 2.3-
fold enriched (FE), n = 44 genes) and ‘positive regula-
tion of nucleobase-containing compound metabolic pro-
cesses’ (Table 3). Five members of the network overlapped
with genes from GWAS significant Obesity loci (Figure 5B,
brown circles) and 6 were from GWAS significant T2DM-
risk loci (blue circles) with one at a GWAS loci associ-
ated with lipids (gold circle). CCDC69 is a network 2 hub
gene (coiled-coil domain containing 69, a cytokinesis pro-
tein (94)) and it regulates the cell-cycle, as does the GWAS-
linked CDK2AP1. Given that the majority of skeletal mus-
cle nuclei are post-mitotic, the gene–environment interac-
tions and/or genetic influencewe note inmusclemay also be
reflective of events in other tissue-types, e.g. ß-cells and/or
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Figure 5. Treatment-responsive IS networks regulate human peripheral insulin sensitivity and link to metabolic disease risk genes. Probabilistic networks
have been utilized to establish a causal relationship between molecules and disease (5). We utilized the dynamic response to diverse forms of treatment
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adipocytes. Indeed, the lncRNA LINC02210 expression in
muscle is positively related to IS but more highly expressed
in ß-cells as compared with muscle or adipose tissue (Sup-
plemental data S3). In sum, this second network appears to
reflect reduced activity of processes that may ultimately re-
flect muscle use: muscle remodeling and substrate cycling as
47 genes were differentially expressed by exercise.
The third network (Supplemental Figure S5) contained
eight genes from loci identified in T2DM and insulin sen-
sitivity GWAS, with a further three linked with obesity
and fasting glucose GWAS loci. While 66% of genes had
a negative relationship to IS, there was no enrichment in
ncRNA (20% ncRNA). P–P interaction analysis contained
33 protein-coding genes involved with the ‘positive reg-
ulation of cellular metabolic processes, signaling’ (FDR
< 1 × 10−5, 2.3 FE) and ‘interaction with host’ (Table
3). Interestingly, the majority of this network was non-
responsive to (‘resistant’) PPAR agonist treatment (56).
However, it did contain 4 genes out of the 16 genes regulated
in vivo following therapeutic lifestyle interventions (Figure
4B) in proportion to changes in IS (GOS2, AGL, LAT3
and ECHDC3). Network 3 included a number of insulin-
and lipid-related signaling molecules (B4GALT6, CDK14,
CERS6, GRB14, FATP1, GOS2, IGF1R, NLK, SLC27A1
and SESN1) (95–102). GRB14 has been consistently linked
to ‘metabolic disease’ and is negatively correlated (R = –
0.36) with IS in the present and other published analyses
(103–105). The network also included regulators of car-
bohydrate homeostasis, (amylo-alpha-1,6-glucosidase, 4-
alpha-glucanotransferase (AGL), a glycogen debranching
enzyme) which were negatively associated with IS. Down-
regulation was associated with improved IS following clin-
ical intervention. Increased SLC27A1 (i.e. fatty acid trans-
port protein 1, FATP1), a plasma membrane long-chain
fatty acid transporter activated by mTORC1 signaling (98),
and lessG0S2 (G0/G1 switch 2)––a negative regulator of li-
pase activity (and a treatment response gene)––was related
to better IS, expanding the evidence base in humans, for the
‘lipid paradox’ and muscle health (106). Thus, network 3
contains genes influenced by ‘substrate turn-over’ (exercise)
rather than metabolic signaling (PPAR activation) with
clear links to substrate storage and utilization.
A fourth network was dominated by non-coding RNAs
(70%, 34 out of the 86 ncRNAs included among CORE-
IS gene list, Table 3 and Figure 6), and required infor-
mation gained from GBA and sense–antisense protein-
coding relationship analysis to provide some biochemical
context. Twelve of the lncRNAs had a total of 16 anti-
sense cis-expressed protein-coding partners demonstrating
positive (6) or negative (10) co-expression (Supplemental
data S3). The combination of these 16 cis-expressed protein-
coding genes and the 15 protein-coding CORE-IS genes
from the module were analyzed for P–P interactions (79).
This yielded a distinct interactive proteome: four gene-sets
(mainly represented by the same 55 genes) were defined as
representing ‘SRP-dependent co-translational protein tar-
geting to membrane’, or ‘viral transcription’; >60 times
enriched over the genome (Bonferroni < 1 × 10−83). A
second group of 38, non-overlapping from the first, were
defined as belonging to ‘viral process’ (19-fold enriched
over the genome, Bonferroni < 1 × 10−34). Gene ontol-
ogy analysis using DAVID, confirmed these extremely en-
riched categories (Supplemental data S8). This ncRNA-
dominated network included some classic metabolic genes,
(COL4A3BP –– also known as CERT or GPBP), a GWAS
loci gene for obesity, and a protein shuttling ceramides and
diacylglycerol. Plausibly, greaterCERT expression combats
the negative impact of lipid molecules on insulin signaling
(106,107) and thus may help to distinguish muscle lipid pro-
file in T2DMpatients from the ‘similarly’ highly lipid-laden
but high IS state of endurance trained muscle (108), reveal-
ing further molecular details of the ‘lipid paradox’ (106).
DISCUSSION
Tissue responses to the hormone insulin (i.e. IS) underpin
glycemic control in humans. Skeletal muscle is the largest
target organ for insulin in humans, and in the post-prandial
state insulin promotes cellular glucose transport for non-
oxidative storage as glycogen. It is a striking observation
that various modes of exercise or drug treatment (50,109–
112) alter IS to a highly variable extent (50,111) such that it
is essential we generate greater understanding of the molec-
ular regulation of IS. In the present study, we have estab-
lished the first robust gene expression signature for IS and
utilized three strategies to validate our findings and explore
the functional implications of our observations: systematic
literature review, quantification of responses to clinical in-
terventions; and application of systems biology methods.
We independently identified many known IS regulators, in-
cluding GRB14, a receptor tyrosine kinase adaptor protein
(113) which inhibits insulin signaling (105,114), located at
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
aimed at reversing insulin resistance, along with measured fasting relationships to estimate if planar filtered networks (77) derived from 191 of the younger
individuals (<70yr), were enriched in genes dynamically regulated or were lncRNAs, harboring causal genetic variant related to metabolic disease, or
dominated by proven T2DM disease pathways. MEGENA (77) was used to identify discrete planar filtered networks using the CORE-IS gene list as
input (FDR <1% and spearman rank correlation; P<0.01 for module significance and P < 0.01 for network connectivity). Follow-up protein–protein
interaction analysis (79) facilitated the interpretation of the identified networks providing additional biological plausibility to each network (78). Node
and label size are proportional to the node degree value within each distinct module. (A) represents the largest discrete planar filtered network (87 genes,
13% ncRNA and 64% negatively co-varying with in vivo fasting IS) that protein–protein interaction analysis identified as being involved with hormone
signaling, including insulin, FDR<1%. This network contained 44% (7; ALDH6A, DHTKD1, KPNA2, MCCC1, PCYT2, PGM2 and RND3) of the 16
genes regulated in vivo proportional to changes in IS, across four independent treatment studies. Further, 33% of the life-style treatment-response genes
(ALDH6A DHTKD1, PCYT2 and RND3) were responsive to three months of PPAR agonist, given to insulin resistant subjects ((Supplemental data S5,
(56)). There were numerous significant GWAS loci for T2DM (gene ID enclosed in blue-ring) or Obesity (gene ID enclosed in brown circle). (B) The second
largest and discrete planar filtered network (81 genes, 22% ncRNA and 75% negatively co-varying with in vivo fasting IS) contained genes from GWAS
loci for T2DM, Obesity and Lipids (gene ID enclosed in gold circle). Twenty-five percent of this network was responsive to anti-diabetes drug treatment
(PPAR agonist), given to insulin resistant subjects for three months (56). Protein–protein interaction analysis indicated that this module was enriched by
genes (33 in the network, FDR < 1 × 10−5) involved in the positive regulation of RNA metabolism and transcription.
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Figure 6. A noncoding RNA network is positively linked to peripheral insulin sensitivity and translational control. Probabilistic networks are utilized
to establish a causal relationship between molecules and disease (5). We utilized the response to diverse forms of treatment aimed at reversing insulin
resistance, along with measured fasting relationships to estimate if planar filtered networks (77), based on data from 191 individuals, were enriched in genes
dynamically regulated or were lncRNAs, harbored causal genetic variant related to metabolic disease, or dominated by proven T2DM disease pathways.
MEGENA (77) was used to identify discrete planar filtered networks using the CORE-IS gene list as input (FDR<1% and spearman gene correlation;
P < 0.01 for module significance and P < 0.01 for network connectivity). Protein–protein interaction analysis (79) facilitated the interpretation of the
identified networks while providing additional biological plausibility to each module (78). Node and label size are proportional to the node degree value
within each distinct module. This, the fourth large discrete planar filtered network was dominated by non-coding RNAs (49 genes, 70% ncRNA, and 84%
of the network members positively co-varying with in vivo IS). Thirteen of the ncRNA had cis antisense expressed protein-coding genes and these 13 genes,
along with the remaining 30% protein-coding CORE-IS genes in the network, formed a protein–protein interaction network strongly associated with viral
responsive protein-coding genes (P < 1 × 10−48) and translational initiation (P < 1 × 10−37). The network included several shorter ncRNAs, including
the highly conserved 7SK ncRNA pseudogenes which are 271 to 326 base-pairs long. The function of these is unknown despite the 7SK ncRNA gene itself
being described half a century ago. 7SK RNA binds to HEXIM1 to inhibit the positive transcription elongation factor b (P-TEFb)––transcript elongation
(HEXIM1 is negatively associated with IS, Table 2 (140) and also regulated by a lncRNA (141).
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a GWAS significant metabolic disease loci, while provid-
ing the first detailed map of the relationship between lncR-
NAs and IS. We may have expected a greater number of
GWAS loci related specifically to insulin, however as noted
above, linear modeling does not fully capture the complex
interactions between genes, insulin, obesity and risk of de-
velopment of T2DM. Further, GWAS have revealed rather
limited numbers of candidate loci for fasting insulin, per-
haps reflecting a lack of a standard approach to measur-
ing fasting insulin (59) across GWAS cohorts. Overall, we
clearly demonstrate that quantitative modeling of RNA can
reveal biological features consistent with both DNA anal-
ysis and biochemical analysis, demonstrating a close and
expected (115) relationship between these three molecular
universes (Table 2).
Biochemical and physiological influences on themolecular as-
sociates of IS
Studying the influence of associated risk-factors for T2DM,
such as self-reported physical activity or diet is fraught with
challenges (116) making the study of the molecular nature
of IS in humans very challenging. Preliminary transcrip-
tomics studies in muscle from T2DM patients claimed to
find a specific PGC1-mediated down-regulation (26) of
OXPHOS genes, concluding that this was a therapeutic-
target for preventing T2DM (117). However, this observa-
tion did not generalize to larger clinical cohorts (22); while
any potential impact of loss of OXPHOS on insulin sig-
naling has been shown to be capricious even in controlled
cell models (88). Instead, single-study observations of re-
duced muscle ‘OXPHOS’ gene expression arise because of
a number of experimental covariates, including using ‘con-
trol’ muscle post ‘hyper-insulinemic clamp’––this acutely
up-regulates OXPHOS pathway transcription in healthy
subjects (i.e. the ‘control’ samples); or when subjects are
not matched for aerobic capacity, physical activity, age or
any combination of the above (24,87,118,119). In fact, even
in skeletal muscle, the IS signature involves a selective al-
teration in AA, and lipid and ketone metabolizing genes
(Table 2) in the complete absence of any loss of OXPHOS
gene expression (n = 564, Figure 3). This indicates qualita-
tive changes in substrate metabolism, rather than a crude
loss of global oxidative capacity potentially underpins the
correlative relationship between circulating BCAA and di-
abetes (47,120), and this would be teleologically consistent
with the high absolute oxidative capacity found in muscle
(purposed for contraction, and not representing a limit to
substrate oxidation rates in resting muscle).
There is evidence that males and females with T2DM suf-
fer different clinical sequela, particularlywith respect to car-
diovascular disease (121). The CORE-IS was not enriched
in genes on the X or Y chromosomes; nor did it contain
genes known to be subject to gender-specific imprinting.
We examined the impact of sexual dimorphism on muscle
gene expression, as this has not been reliably assessed be-
fore, and found 650 genes with sexual dimorphic gene ex-
pression (1%FDR, n = 89 per sex, Supplemental data S9)
and this included 15% of the CORE-IS genes. Interestingly,
the expression of a type II muscle fiber-type splice-variant
(from the RYR1 gene) was lower expressed in women (Sup-
plemental data S9); however, this prototype muscle fiber-
type biomarker (43) did not correlate with IS. Thus, with
our global transcriptomic methods, a modest relationship
between sex, IS and muscle gene expression is detectable;
potentially reflecting small differences in fiber-type compo-
sition, along with environmental factors, and this may con-
tribute to differences in T2DM risk and disease progression
between the genders (122). Far larger intervention studies,
including many hundreds of both sexes, matched for physi-
ological status, are required to robustly analyze if any vari-
ation in the responses to treatment reflects sexual dimor-
phism influenced genes, and thus this was not attempted in
the present study.
Non-coding transcriptome generates novel insights into IS
Using RNA-seq, the Illumina Human BodyMap and
Genotype-Tissue Expression Project (GTEx, (30)) has re-
ported a median count of less than 5000 lncRNA genes
across a large number of human tissue and cell types (123),
often with only a few hundred per tissue-type. The present
analysis, which relies on a probe-level signal filter (study
specificity), a secondary transcript-level ‘noise’ filter and
confirmation that the low-end of the dynamic expression
range equates to known low-expressed RNA and proteins
(Supplemental data S10 and raw data), demonstrates the
advantages of our new approach to customising array pro-
cessing to tissue/study specific patterns of RNA detection.
Further, based again on RNA-seq observations, there is a
belief that lncRNAs are expressed in a highly cell-type spe-
cific manner. For example, the lncRNA antisense for PDX1
(PDX1-AS or ’PLUTO’) - promotes expression of PDX1 in
in ß-cells via regulation of chromatin - is down-regulated in
T2DM (45). While reported as ‘ß-cell specific’, we observed
PLUTO to be expressed in skeletal muscle at a value equal
to islet cell-line HTA 2.0 data (EndoC-ßH1 cells), while
PDX1 is 8-fold lower expressed inmuscle than in islets (Sup-
plemental data S10). Thus, while there are clearly further
methodological factors to consider before we have a defini-
tive view on the human transcriptome, the present analysis
indicates that current representations of the ncRNA tran-
scriptome by the Illumina Human BodyMap and GTEx
are far from comprehensive, with reported tissue specific ex-
pression patterns being inaccurate. Notably, the IS-related
ncRNAs in the present study are equally expressed in mus-
cle, islet cells and adipose tissue (Figure 6 and Supplemental
data S3) implying that they have the potential to impact on
multiple aspects of insulin biology.
Akerman et al recently reported that modulation of
lncRNA in islet cells impacts genes expression both in
cis and trans, and impacts insulin production and secre-
tion in vitro (45). Further, six ncRNAs were dysregulated
in islet samples from people with impaired glucose tol-
erance and T2DM. Of these ncRNAs, we could only lo-
cate AC009487.1 in the current reference genome, and this
gene was not detected in skeletal muscle. We did find in
vivo regulation of ncRNAs in relation to peripheral IS be-
fore and after treatment aimed at improving IS (Figure
2; Supplemental data S3, S5, and S8). Strikingly, eleven
ncRNAs were regulated by treatment and some directly in
proportion to IS improvements; these included PRKCQ-
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AS1, which is anti-sense to the gene coding for PKC-,
a known regulator of insulin signaling and also a drug-
target for T2DM (83–85). We were one of the first groups
to report in vivo interactions between lncRNA and a cis-
expressed protein coding gene in humans (124). In the
present study, we found that expression of PRKCQ-AS1
and the mRNA for PKC- (PRKCQ) co-varied in vivo (Fig-
ure 2)––although the slope of the relationship indicates a
modest interaction. In vitro loss of PRKCQ-AS1 was asso-
ciated with greater expression of PRKCQ (Figure 2D, (P =
0.05, n= 12 transfections). This suggests that PRKCQ-AS1
may act to maintain a relatively constant level of PRKCQ,
despite fluctuations in transcription from that locus. Like
other sense-antisense partners, e.g. PDX1/PDX1-AS, co-
expression can also be reflective of regional chromatin sta-
tus and hence transcription from that genomic locus (45).
A ncRNA antisense transcript at the Sorbin and SH3 do-
main containing three (SORBS3) loci, AC037459.2, was
also related to fasting IS. SORBS3––which codes for the
protein vinexin––is down-regulated in the muscle of obese
individuals, with a 5–25% increase in cytosine methylation
at the SORBS3 locus (125). Nonetheless, despite changes
in expression of ENTPD1-AS1, NPSR1-AS1 and TTN-
AS1 being positively associated with improvements in IS,
and negatively associated for ATP13A4-AS1 and RORA-
AS2, transcripts at the SORBS3 locus were stable to clin-
ical intervention in our analysis. Further, detailed studies
aremerited, especially with respect to the complexPRKCQ-
AS1/PRKCQ locus, given the importance of PKC- for in-
sulin biology (84).
Quantitative measures of RNA and interpretation of
metabolic disease GWAS loci
Notably, when we compared the CORE-IS list with a re-
cently published study that appraised extreme IR in a small
group of obese individuals there was 100% concordance for
directionality for the genes in common to both studies (Sup-
plemental data S11, (126)). This would support the interpre-
tation that the present CORE-IS signature represents the
natural trajectory of obesity-related metabolic disease and,
due to the continuous/quantitative nature of RNA data, we
believe that the CORE-IS signature is potentially suitable
for use as a drug-screen aimed at finding treatments for im-
proving IS. So far, the majority of genome-wide association
markers related to human disease do not occur within the
sequence coding the processed transcript, but rather occur
at regulatory regions potentially impacting on transcrip-
tion, as well as RNA stability and translation (127). There
has been limited progress moving from GWAS loci candi-
date regions to the identification of the potential gene re-
sponsible for the clinical associations, partly reflective of ex-
tensive linkage disequilibrium (14). Thus, identification of
45 GWAS-MD genome-wide significant loci (plus an ad-
ditional nine GWAS significant from the network-analysis
and >150 statistically weaker associations) indicates that
network modeling of RNA (77) provides an opportunity to
examine the continuous quantitative relationship between
a genomic disease risk loci and the phenotype in question,
something that is not possible with DNA sequence alone.
It is important to state that there were no occasions when
a CORE-IS gene only occurred at non-GWAS-MD gene
using the Type 2 Diabetes knowledge portal (it contains
GWAS results beyond metabolic disease). Further, in ∼5%
of occasions GWAS-MD significant CORE-IS genes were
associated with a non-metabolic disease at the ‘GWAS’ or
a ‘suggestive association’ level, (but in most cases this non-
metabolic phenotype was ‘Height’, which is related to body
size and BMI calculation).
Gibson et al has demonstrated that global eQTL anal-
ysis can be an effective strategy for identifying the func-
tional gene at GWAS loci for individual diseases (128). In-
deed, large scale eQTL analysis of adipose tissue samples
provides support for 14 of the GWAS-MD loci mentioned
above, of which 7 increased the risk for T2DM. Genotype-
transcript associations have also been observed in human
pancreas islets, using cis-exon-eQTL mapping (129); where
∼2000 samples were required to identify an eQTL captur-
ing 1% heritability (19). Van de Bunt et al. reported 2341
(or 6% of RNA-seq detectable genes) with an exon-eQTL
within 250 kb of the transcription start site (an arbitrary dis-
tance) and 44 of these eQTL genes were related to periph-
eral IS in our analyses (Supplemental data S12). Further
exploration of the CORE-IS gene-list using network analy-
sis (77) in hepatic and adipose tissue would no doubt reveal
additional commonalities across tissues; however, this will
require newRNAdatasets using RNAquantificationmeth-
ods consistent with the present study, which should over-
come limitations in short-read RNA-seq (30,37), thus po-
tentially circumventing some of the challenges faced when
implementing eQTL methodologies (19).
Network structures and dynamics responses of the CORE-IS
genes
Using scale-free planar filtered network analysis (Table
3), we mapped the network structure of the CORE-IS
genes (77). This approach––well suited to RNA profiles
from a relatively cell-type homogenous tissue like skeletal
muscle––reveals the regulatory interactions underlying in-
sulin sensitivity as well as smaller functional sub-clusters
of genes (modules). For example, we found GRB14 closely
co-expressed with six additional genes, including an aro-
matic AA transporter––SLC16A10 (TAT1, Supplemental
Figure S5). Using transcription factor analysis (63), we
noted that four of these genes (GRB14,HOMER1, KPNA5
and SLC16A10) had HNF1A type binding sites (Z-score =
9.3);HNF1A occurs at aGWAS risk loci for T2DM(71) and
loss-of-function ofHNF1A is related to familial early-onset
diabetes (130). HNF1A type transcription factor binding
sites were also enriched in CORE-IS genes differentially
expressed following exercise-training (Z-score = 15.3) and
interestingly polymorphisms in HNF1A are also linked to
muscle histological phenotype (131), while this transcrip-
tion factor also plays an established role in the pancreas.
This illustrates the potentially pervasive influence of disease
risk genes across multiple organs and the layers of genomic
variants which influence the regulation of the expression of
the CORE-IS genes.
Unique to the present analysis, we were able to iden-
tify a molecular signature that is regulated in proportion
to the success of clinical interventions aimed at combat-
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ing T2DM. A subset of 16 of the CORE-IS genes quanti-
tatively related to improvement in insulin action in four di-
verse clinical studies, providing a major step toward iden-
tifying a molecular basis for the variable improvements in
IS observed following standardized exercise/life-style inter-
ventions (48,50). One quarter were related to amino-acid
metabolism (ALDH6A1, DHTKD1, LAT3 and MCCC1)
and were positively linked to IS; four genes were ‘sub-
strate’ metabolism genes (AGL, G0S2, KPNA2 and PGM2)
involved in either blocking substrate mobilization or up-
regulating glycolytic capacity, all negatively linked to IS
and four were located at GWAS significant loci. PRRX1
is involved in pancreatic developmental and modulating
adipogenesis via TGF activity (132), a key pathway in-
volved in the positive cardiovascular adaptation to en-
durance exercise (20,133), was positively associated with IS
responses. This 16-gene signature represents a potentially
useful insulin-target tissue biomarker for examining the re-
sponses to novel treatments aimed at improving IS.
In many of the largest GWAS studies, variation in fasting
insulin was related to BMI with a shared variance of ∼33%
(86) and statistical adjustment for BMI facilitated GWAS
analysis. Recent studies have linked (implied causality) risk
phenotypes for IR (e.g. elevated BMI, fasting glucose, fast-
ing triglycerides (TG) or reduced HDL (69)) with GWAS
significant loci. This has led to the emerging concept of fail-
ure in ‘adipose tissue capacity’ to adapt to over-feeding,
promoting ectopicmuscle and liver IR (69). Lotta et al com-
bined information from 53 loci associated with higher fast-
ing insulin, as well as lipids; a 53-SNP genetic score which
associated with poor insulin sensitivity in >7000 indepen-
dent subjects and a 12% increased relative risk for T2DM
(69) and a lower rate of peripheral adipose tissue ‘accumu-
lation’. This genetic estimate of IR status, was related to
higher concentrations of all 3 BCAA’s (134) and included
5 CORE-IS genes from the present study (GRB14, MCC,
LPL, PPP1R3B and INSR). A gain of functionmutation in
the lipid ‘mobilizing’ gene, LPL, is associated with better IS
and protection from T2DM (69). Consistent with this, mus-
cle LPL mRNA expression was positively associated with
IS (n = 564, R = 0.35, FDR < 1%). It is understood that
under normal physiological conditions in humans, a high
proportion of body mass is attributable to skeletal muscle
(∼40%), such that the same risk genes may relate to IS in
both adipose and muscle tissue compartments, incorporat-
ing aspects of tissue plasticity that are common to adipose
and muscle (20,135). Development and application of an
appropriately validated multi-RNA risk-score will capture
more clinical variance, and hence offers greater potential
than the aforementioned 53-SNP genetic score.
In conclusion, based on the production and data model-
ing of a total of 1012 human muscle RNA profiles, as well
as a new tissue-specific approach to substantially enhance
the analysis of high-density DNA arrays, we produced a ro-
bust and highly validated global molecular model of human
peripheral insulin sensitivity. Themodel revealed a novel in-
terpretative structure for potentially exploring the dynamic
interactions of metabolic-disease GWAS loci and, for the
first time, illustrates the network interactions between the
coding and non-coding IS transcriptome. Among other im-
plications, this work lays the foundation for the discovery
of novel biomarkers for metabolic disease and a tool for in
vitro drug-screening.
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